0 citations0 references

<p>Gastric Signet Ring Cell Carcinoma: Current Management and Future Challenges</p>

Cancer Management and Research2020Vol. Volume 12, pp. 7973–7981

Citations Over TimeTop 10% of 2020 papers

Yang Li, Zhikai Zhu, Fuhai Ma, Liyan Xue, Yantao Tian

Abstract

Recent advances in the epidemiology, pathology, molecular mechanisms, and combined modality therapy (CMT) fields have shown that gastric signet ring cell carcinoma (GSRC) should be considered a distinct cancerous entity. Clinical management of this cancer is challenging, with chemoradioresistance and poor outcomes in advanced stages. Pathological and molecular sets of GSRC demonstrate different features of poor cohesion and differentiation according to the WHO, Japanese Gastric Cancer Association, and Laurén classifications. These features also result in poor response to adjuvant and neoadjuvant chemoradiotherapy. Certain studies of GSRC showed the disputed effectiveness of hyperthermic intraperitoneal chemotherapy and immunotherapy. Our aim was to discuss how an improved understanding of these therapeutic benefits may provide better treatment selection for patients, and therefore improve survival. The challenges in the new understanding of GSRC in routine practice and pathology, and the current limitations of treatment will also be discussed.

Related Papers

[Clinicopathological features and prognostic analysis of patients with signet ring cell gastric carcinoma].(2015)
[Apparently bladder origin signet ring cell carcinoma: a case report].(1990)
→ IDDF2019-ABS-0175 Differences in biologic behaviors between mixed and pure signet ring cell carcinoma in chinese early gastric cancer patients(2019)
→ Primary signet ring cell carcinoma of the colon masquerading as foamy histiocytic collections on preoperative biopsy(2022)
→ Response:(2018)